Skip to main content
Publications
Kovesdy CP, Ebert N, Vizcaya D, Walsh M, Kosiborod MN, Layton JB, Ziemiecki R, Johannes CB, Pladevall-Vila M, Gee PO, Jefferson N, Chicoye A, Lopes M, Thapa BB, Curhan G, Rangel L, Bhartia M, Liu F, Farjat AE, Oberprieler NG. Change in urine albumin-creatinine ratio and occurrence of hyperkalemia in patients initiating finerenone in the United States: a cohort study from the FOUNTAIN platform. Nephron. 2025 Feb 27;1-26. doi: 10.1159/000543923
Cheol Lee J, Hung JY, Kim YC, Chang GC, Soo Yoo S, Yang SH, Davis KL, Nagar SP, Taylor A, Yong Lee S, Shih JY. Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first line, first- or second-generation EGFR tyrosine kinase inhibitor in South Korea and Taiwan. Asian Pac J Cancer Bio. 2021 May 20;6(2). doi: 10.31557/APJCB.2021.6.2.123-132
